JP2012502047A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502047A5
JP2012502047A5 JP2011526201A JP2011526201A JP2012502047A5 JP 2012502047 A5 JP2012502047 A5 JP 2012502047A5 JP 2011526201 A JP2011526201 A JP 2011526201A JP 2011526201 A JP2011526201 A JP 2011526201A JP 2012502047 A5 JP2012502047 A5 JP 2012502047A5
Authority
JP
Japan
Prior art keywords
ranolazine
amiodarone
per day
administered
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/055924 external-priority patent/WO2010028173A2/en
Publication of JP2012502047A publication Critical patent/JP2012502047A/ja
Publication of JP2012502047A5 publication Critical patent/JP2012502047A5/ja
Pending legal-status Critical Current

Links

JP2011526201A 2008-09-04 2009-09-03 心房細動を治療する方法 Pending JP2012502047A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9435908P 2008-09-04 2008-09-04
US61/094,359 2008-09-04
US10877608P 2008-10-27 2008-10-27
US61/108,776 2008-10-27
PCT/US2009/055924 WO2010028173A2 (en) 2008-09-04 2009-09-03 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
JP2012502047A JP2012502047A (ja) 2012-01-26
JP2012502047A5 true JP2012502047A5 (en:Method) 2012-10-18

Family

ID=41421639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526201A Pending JP2012502047A (ja) 2008-09-04 2009-09-03 心房細動を治療する方法

Country Status (5)

Country Link
US (1) US20100056536A1 (en:Method)
EP (1) EP2337559A2 (en:Method)
JP (1) JP2012502047A (en:Method)
CA (1) CA2735653A1 (en:Method)
WO (1) WO2010028173A2 (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523873T3 (es) * 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
NZ598942A (en) * 2009-07-27 2014-02-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (en:Method) 2011-07-01 2018-04-28
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
PT3083608T (pt) 2013-12-19 2018-11-09 Gilead Sciences Inc Compostos heterocíclicos fundidos como moduladores de canal iónico
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AU2498100A (en) * 1999-01-11 2000-08-01 Board Of Regents Of The University And Community College System Of Nevada, The Use of an amiodarone compound as antifungal agent
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine

Similar Documents

Publication Publication Date Title
JP2012502047A5 (en:Method)
US8969400B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
JP2018514534A5 (en:Method)
JP2014528474A5 (en:Method)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2012193216A5 (en:Method)
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
JP2013508289A5 (en:Method)
McLoughlin et al. Therapy of Helicobacter pylori
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2013516493A5 (en:Method)
JP2020504129A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
JP2020500864A5 (en:Method)
EP3226873A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
JP2016505050A5 (en:Method)
JP2016512247A5 (en:Method)
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
JP2011500589A5 (en:Method)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
JP2019507786A5 (en:Method)